Removal from liver transplantation list of a hepatitis C virus‐HIV co‐infected patient after successful treatment with sofosbuvir and daclatasvir. Issue 3 (9th June 2016)

• Record Type: Journal Article
• Authors: Llaneras, J.; Castells, L.; Santos, B.; Crespo, M.; Puig, T.; Esteban, J.I.; Esteban, R.
• Is Part Of: Transplant infectious disease. Volume 18:Issue 3(2016)
• Page Start: 442
• Page End: 445
• Publication Date: 2016-06-09
• Subjects: sofosbuvir -- daclatasvir -- hepatitis C virus -- human immunodeficiency virus -- transplant; Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12538
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: We present a human immunodeficiency virus‐infected patient with severe decompensated hepatitis C virus‐related cirrhosis awaiting liver transplantation (LT) who received a 24‐week course of interferon/ribavirin‐free antiviral treatment with sofosbuvir and daclatasvir on a compassionate basis. Rapid viral suppression was associated with progressive improvement of his liver function tests. The patient achieved a sustained virological response and concomitant clinical improvement, which prompted removal from the LT list 12 weeks after the end of treatment.